Malignancy and Psoriasis Treatment
Dr Cohen explores the association between psoriasis and increased malignancy risk, particularly keratinocyte carcinoma (BCC and SCC), lymphoma, bladder cancer, and lung adenocarcinoma. While TNF inhibitors raise the most concern—especially for lympho-articular malignancies—current data do not establish a direct link between biologic therapies and cancer risk. Managing psoriasis in patients with a history of malignancy requires individualized assessment and oncologist collaboration. Importantly, even patients actively undergoing cancer treatment may still be candidates for biologics, offering them significant relief from psoriasis-related burden when deemed safe.
Jeffrey M. Cohen, MD is a board-certified medical dermatologist and the director of the psoriasis treatment program at the Yale School of Medicine in New Haven, CT.
© 2025 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of The Dermatologist or HMP Global, their employees, and affiliates.
The APP Institute is dedicated to educating and informing advanced practice providers on clinical topics and practical issues to support the profession and improve the quality of patient care across the spectrum of dermatology.
The Derm APP is designed for Advanced Practice Providers who specialize in Dermatology, to further their education and increase their knowledge to achieve better patient outcomes. Explore cutting-edge research, innovative treatment options, and new therapeutic methods, while remaining focused on the fundamental principles and terminology associated with dermatology. Engage year-round with The Dermatologist to access clinical insights, interactive features, research news updates, accredited continuing education programs, and more.
